ResearchRSS3 days ago
Scientists discovered that a protein called UBQLN2 helps nerve cells manage both proteins and fats. When UBQLN2 doesn't work properly — especially in controlling fats — it may cause nerve cells to die in ALS, a disease that weakens muscles over time. This discovery suggests doctors might be able to help nerve cells stay healthier by fixing how fats are controlled.
WHY IT MATTERSUnderstanding how fat regulation breaks down in ALS nerve cells could lead to new treatments that target this specific problem, potentially slowing or stopping nerve cell damage in people living with ALS.
NewsRSS3 days ago
A person living with ALS is sharing their experience about staying active and maintaining muscle strength. They were unsure whether to write about this topic because they worried people might misunderstand their message. The author emphasizes that everyone with ALS may need to find their own approach to managing the disease.
WHY IT MATTERSThis personal perspective helps ALS patients understand that maintaining mobility is individual—what works for one person may not work for another, so they shouldn't feel pressured to follow someone else's exact approach.
NewsRSS3 days ago
A doctor named Richard Lewis shares his approach to telling patients they have ALS (a disease that affects nerve cells that control muscles). The article focuses on how he explains the diagnosis, talks about things that are uncertain, and helps patients and families cope with the news.
WHY IT MATTERSLearning how doctors communicate an ALS diagnosis can help patients and families understand what to expect when receiving their own diagnosis and how to have better conversations with their care team.
ResearchRSS3 days ago
A new study from Denmark found that people with higher levels of HCB (a pesticide that was banned in many countries) in their blood may have a higher risk of developing ALS, a disease that affects nerve cells and causes muscle weakness. HCB was used as a pesticide in the past but is no longer allowed in many places because it can be harmful to health. This research suggests that exposure to this old pollutant might be connected to ALS risk.
WHY IT MATTERSIf you have ALS or a family history of it, understanding environmental risk factors like HCB exposure could help you and your doctor identify potential causes and discuss ways to reduce exposure to similar pollutants.
NewsRSS3 days ago
Pseudobulbar affect (PBA) is a condition where people with ALS have sudden, uncontrollable crying or laughing that doesn't match what they're actually feeling. A doctor named Richard Lewis explains what causes PBA, what it looks like, and shares a specific question he uses to ask patients about it—because many people don't mention this symptom unless directly asked.
WHY IT MATTERSMany ALS patients experience PBA but don't report it to their doctors, so learning the screening question could help you get diagnosed and treated for this treatable symptom that affects quality of life.
Clinical trialRSS3 days ago
AB Science is preparing to test an experimental drug called masitinib for ALS (a disease that affects nerve cells that control muscles). To protect their investment in this large clinical trial, the company bought special insurance that would reimburse them if the trial doesn't go as planned or costs more than expected.
WHY IT MATTERSThis insurance arrangement signals that AB Science is confident enough in masitinib to move forward with Phase 3 testing in ALS patients, which is a critical step toward potentially bringing a new treatment option to people living with this progressive disease.
NewsRSS3 days ago
This article discusses how people living with SMA (spinal muscular atrophy) can maintain healthy friendships with their caregivers, even when conflicts arise. The author emphasizes the importance of their caregiver community and explores ways to resolve disagreements while keeping these important relationships strong.
WHY IT MATTERSPeople with SMA depend on caregivers for daily support, making it crucial to know how to address conflicts constructively without damaging relationships that are essential to their health and independence.
AdvocacyRSS3 days ago
Delphine Andrews, a life coach and disability advocate from North Carolina who lives with SMA (spinal muscular atrophy), shared her personal story in a podcast interview. She discussed how she learned to accept herself, help others with disabilities, and build a career as a life coach. The episode also covered important topics like managing caregivers and understanding how different parts of someone's identity intersect.
WHY IT MATTERSHearing from someone living with SMA about practical strategies for self-acceptance, caregiver management, and career transition can help newly diagnosed patients and families navigate similar challenges in their own lives.
ResearchRSS3 days ago
Researchers found that a simple electrical test using surface electrodes on the skin can measure nerve signals in people with spinal muscular atrophy (SMA). These signals were much weaker in SMA patients compared to healthy people, which suggests this test could be a useful way to track how the disease changes over time.
WHY IT MATTERSIf validated, this non-invasive surface electrode test could provide a faster, easier, and cheaper way to monitor SMA progression in clinical trials and patient care compared to current muscle strength assessments.
ResearchRSS3 days ago
A large study in the UK followed over 500,000 people for about 10 years and found that breathing polluted air for a long time does not appear to increase the risk of getting ALS, a disease that affects nerve cells that control muscles. Fewer than 1,000 people in the study developed ALS during the study period. This suggests that air pollution may not be an important risk factor for developing ALS.
WHY IT MATTERSIf you have ALS or are worried about developing it, this study suggests that long-term air pollution exposure is unlikely to be a major cause, which may help reduce anxiety about environmental risk factors you cannot easily control.
ResearchRSS3 days ago
Scientists discovered that some people with ALS (a disease that affects nerve cells controlling muscles) may develop the condition from new mutations that happen by chance in their nerve cells, rather than inheriting the mutation from their parents. This is different from inherited ALS cases where a parent passes down a faulty gene. This finding suggests there are multiple ways ALS can develop, which could help doctors better understand and treat the disease.
WHY IT MATTERSIf your ALS diagnosis is sporadic (not inherited), this research suggests your condition may have developed from random mutations in your nerve cells rather than a genetic predisposition, which could change how doctors approach your treatment and genetic counseling.
Clinical trialCLINICALTRIALS5 days ago
Researchers are looking for adults and children with certain immune system disorders to join a study. The immune system normally helps your body fight infections, but in some people it doesn't work properly, causing frequent infections and other health problems. This study wants to understand why some immune systems fail and how to help people with these conditions. Relatives of affected people may also be able to join.
WHY IT MATTERSThis trial is actively recruiting 500 participants with four specific genetic immune disorders (PI3KCD, CTLA4, STAT3GOF, and MAGT1 deficiency) — if you or a family member has one of these diagnoses, you may be eligible to enroll now and contribute to understanding these rare conditions.
PolicyRSS5 days ago
The FDA announced it has completed its first year of goals to reduce the use of animals in drug testing. The agency launched several new programs to replace animal testing with alternative methods that are often faster and more accurate. This shift means new medicines can be developed and tested in ways that don't require testing on animals.
WHY IT MATTERSFaster, more reliable drug testing methods could accelerate the development and approval of treatments for rare diseases, potentially bringing new therapies to patients years sooner than traditional animal testing timelines allow.
ResearchBIORXIV5 days ago
Researchers analyzed blood samples from over 5,400 people with rare genetic diseases to see if a test called RNA-Seq could help find the genetic cause of their conditions. They found that this blood test works better for some diseases than others, and they used special computer programs to spot unusual gene activity patterns that might explain why people got sick. This study shows that blood tests could be a useful tool to help diagnose rare diseases alongside other genetic tests.
WHY IT MATTERSIf you have an undiagnosed rare disease, this research suggests blood-based RNA testing could help identify the genetic cause—potentially leading to a diagnosis after years of searching.
ResearchCLINICALTRIALSApr 17
Researchers completed a study that collected information about how Canavan disease develops and progresses in children. The study looked at medical records from 67 patients and also gathered new information about their movement abilities and important health milestones. This type of study helps doctors understand the disease better and can guide future treatment development.
WHY IT MATTERSThis completed natural history study provides detailed data on how Canavan disease progresses in children, which is essential for designing future clinical trials and understanding what to expect from the disease.
PolicyRSSApr 13
The FDA sent reminders to over 2,200 companies and research groups telling them they must share their clinical trial results on a public website called ClinicalTrials.gov. This is a requirement, not optional. The FDA is making sure that information about how medical treatments work—whether they help patients or cause problems—gets shared publicly so everyone can see the results.
WHY IT MATTERSWhen companies hide negative trial results, patients may not know the full picture about whether a treatment actually works, which could affect decisions about whether to participate in a trial or use a medication.
ResearchBIORXIVApr 13
A research study about how parents cope when their children have rare diseases and doctors can't quickly figure out what's wrong was withdrawn from a scientific website. The authors submitted the study with false information, so it is no longer available for other researchers to read or use.
WHY IT MATTERSThis withdrawal highlights the importance of verifying research quality and integrity — families relying on studies about rare disease diagnosis need accurate, trustworthy information to guide their own experiences.
ResearchPUBMEDApr 12
Researchers in Canada studied 715 patients with rare diseases who had their entire genome sequenced (a test that reads all of a person's genetic code). The study found that genome sequencing helped doctors in many ways: it confirmed diagnoses in some patients, changed how doctors treated 36% of patients, found new research opportunities, and identified genetic information that relatives should know about. The test also helped doctors avoid unnecessary tests in 88% of cases.
WHY IT MATTERSIf you have an undiagnosed rare disease, this research shows that whole genome sequencing can help your doctor find answers and change your treatment plan — and it may also reveal important genetic information for your family members.
ResearchPUBMEDApr 10
This study talked to 10 parents in South Africa whose children have rare diseases to understand what challenges they face as caregivers. The parents said they struggle with stress, worry about their children's health, and sometimes feel tired and sad. The researchers want doctors and hospitals to better understand what caregivers go through so they can offer more help and support.
WHY IT MATTERSIf you're caring for a child with a rare disease, this research validates that your struggles are real and documented — and shows healthcare systems need to provide better caregiver support services.
ResearchPUBMEDApr 10
Doctors from around the world created a network called the International Neuroblastoma Risk Group to share information about neuroblastoma, a type of cancer that starts in nerve cells. They combined data from over 25,000 patients to help researchers understand the disease better and develop better treatment plans. This teamwork model shows how rare cancer research can be improved when hospitals and countries work together.
WHY IT MATTERSPatients with neuroblastoma now benefit from standardized treatment approaches and risk classifications developed through this international collaboration, which means more consistent and potentially better care regardless of where they receive treatment.